[ATRS] Antares Pharma, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Medical/Dental Instruments

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 2.38 Change: 0.16 (7.21%)
Ext. hours: Change: 0 (0%)

chart ATRS

Refresh chart

Description: Antares Pharma, Inc. operates as a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide. The company?s injection products include OTREXUP, a pre-filled methotrexate syringe with Medi-Jet technology to enable rheumatoid arthritis (RA) and psoriasis patients to self-inject methotrexate at home; and Tjet/Zomajet, the needle-free auto injectors to deliver human growth hormone treatment to children without the use of a needle. Its transdermal products comprise Gelnique3%, an oxybutynin gel product for the treatment of overactive bladder; and Elestrin, a transdermal estradiol gel for the treatment of moderate-to-severe vasomotor symptoms associated with menopause. The company is also developing OTREXUP for the treatment poly-articular-course juvenile RA and psoriasis; Vibex QS T for testosterone replacement therapy for men suffering from symptomatic testosterone deficiency; Vibex auto injectors; and disposable

Fundamental Ratios
Shares Outstanding EPS-0.14 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 31.94% Sales Growth - Q/Q-0.64% P/E-20.71
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-56.49% ROE-94.3% ROI
Current Ratio1.97 Quick Ratio1.69 Long Term Debt/Equity Debt Ratio0.6
Gross Margin53.67% Operating Margin-111.47% Net Profit Margin-111.8% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities-10 K Cash From Investing Activities180 K Cash From Operating Activities-10.66 M Gross Profit4.67 M
Net Profit-6.79 M Operating Profit-6.74 M Total Assets58.67 M Total Current Assets41.36 M
Total Current Liabilities21.05 M Total Debt Total Liabilities23.52 M Total Revenue8.35 M
Technical Data
High 52 week3.89 Low 52 week2.36 Last close2.81 Last change-1.4%
RSI49.45 Average true range0.14 Beta0.72 Volume2 M
Simple moving average 20 days-1.77% Simple moving average 50 days-6.77% Simple moving average 200 days-12.28%
Performance Data
Performance Week-3.44% Performance Month3.69% Performance Quart-12.19% Performance Half-15.36%
Performance Year9.34% Performance Year-to-date3.31% Volatility daily2.84% Volatility weekly6.35%
Volatility monthly13.01% Volatility yearly45.07% Relative Volume377.1% Average Volume1.15 M
New High2.16% New Low

News

2020-05-28 07:07:00 | Why Is This Fast-Growing Biotech So Undervalued?

2020-05-27 07:00:10 | Antares Pharma to Present at the Jefferies Virtual Healthcare Conference

2020-05-20 22:04:52 | Edited Transcript of ATRS earnings conference call or presentation 5-May-20 12:30pm GMT

2020-05-05 21:30:45 | Antares Pharma Inc ATRS Q1 2020 Earnings Call Transcript

2020-05-05 12:24:00 | Why Antares Pharma Is Crashing 12.3% Today

2020-05-05 07:00:10 | Antares Pharma Reports First Quarter 2020 Operating and Financial Results

2020-04-28 07:00:10 | Antares Pharma to Report First Quarter 2020 Operating and Financial Results

2020-03-22 00:20:38 | Edited Transcript of ATRS earnings conference call or presentation 3-Mar-20 1:30pm GMT

2020-03-03 07:51:51 | The Daily Biotech Pulse: GenMark Diagnostics Ships COVID-19 Test Kits, Karyopharm To Offer Shares, And More

2020-03-03 07:00:10 | Antares Pharma Reports Fourth Quarter and Full Year 2019 Operating and Financial Results

2020-03-01 09:20:13 | Health Check: How Prudently Does Antares Pharma NASDAQ:ATRS Use Debt?

2020-02-26 07:00:10 | Antares Pharma to Present at the Cowen and Company 40th Annual Health Care Conference

2020-02-25 07:00:10 | Antares Pharma to Report Fourth Quarter and Full Year 2019 Financial and Operating Results

2020-01-27 07:00:10 | Antares Pharma Announces Full-Year 2020 Net Revenue Guidance Range of $135 to $155 Million

2020-01-16 05:59:44 | Is Antares Pharma, Inc.'s NASDAQ:ATRS CEO Paid At A Competitive Rate?

2019-12-14 17:20:13 | Here is What Hedge Funds Think About Antares Pharma Inc NASDAQ:ATRS

2019-12-10 07:00:10 | Antares Pharma Appoints Edward Tykot Senior Vice President, Corporate Development

2019-12-06 07:00:10 | Antares Pharma Social Media Campaign for XYOSTED® Wins MarCom Platinum Award

2019-12-02 09:49:13 | An Intrinsic Calculation For Antares Pharma, Inc. NASDAQ:ATRS Suggests It's 43% Undervalued

2019-11-27 17:51:22 | Antares Pharma to Present at the 31st Annual Piper Jaffray Healthcare Conference

2019-11-20 07:25:05 | The Daily Biotech Pulse: Endo's Cellulite Treatment Accepted For Review, Diffusion Pharma Reports Positive Glioblastoma Data

2019-11-19 07:00:00 | REMINDER: Antares Pharma Enters Into a Global Development Agreement With Idorsia Pharmaceuticals Ltd.

2019-11-19 01:00:00 | Antares Pharma Enters Into a Global Development Agreement With Idorsia Pharmaceuticals Ltd.

2019-11-13 07:00:00 | Antares Pharma to Present at the Jefferies 2019 London Healthcare Conference

2019-11-09 08:19:55 | Edited Transcript of ATRS earnings conference call or presentation 5-Nov-19 1:30pm GMT

2019-11-05 07:00:00 | Antares Pharma Reports Third Quarter 2019 Operating and Financial Results

2019-11-01 11:49:48 | Hedge Funds Are Selling Antares Pharma Inc ATRS

2019-10-31 07:00:05 | Antares Pharma Announces Receipt of Final Payment From Sale of Zomajet™ Needle-Free Delivery System

2019-10-29 07:00:05 | Antares Pharma to Report Third Quarter 2019 Financial and Operating Results

2019-10-24 07:00:05 | Antares Pharma Announces Two Poster Presentations at the 2019 Sexual Medicine Society Scientific Annual Meeting

2019-10-17 06:55:37 | Do Directors Own Antares Pharma, Inc. NASDAQ:ATRS Shares?

2019-09-17 07:00:00 | Antares Pharma to Present at the Ladenburg Thalmann 2019 Healthcare Conference

2019-09-11 11:50:49 | Does Antares Pharma NASDAQ:ATRS Have A Healthy Balance Sheet?

2019-08-20 08:09:00 | Teva says FDA-approved generic EpiPen is now available in the U.S. for $300 for a 2-pack

2019-08-07 00:30:36 | Edited Transcript of ATRS earnings conference call or presentation 6-Aug-19 12:30pm GMT

2019-08-06 17:23:34 | Antares Pharma Inc ATRS Q2 2019 Earnings Call Transcript

2019-08-06 15:00:44 | Loss-Making Antares Pharma, Inc. NASDAQ:ATRS Expected To Breakeven

2019-08-06 07:00:00 | Antares Pharma Reports Second Quarter 2019 Operating and Financial Results

2019-07-30 07:00:00 | Antares Pharma to Report Second Quarter 2019 Financial and Operating Results

2019-06-27 07:00:00 | Antares Pharma Announces Amendment to Existing Loan and Security Agreement With Hercules Capital

2019-06-26 14:08:45 | Here is What Hedge Funds Think About Antares Pharma Inc ATRS

2019-06-11 07:00:00 | Antares Pharma to Present at the Raymond James 2019 Life Sciences and MedTech Conference

2019-06-06 11:45:34 | Have Insiders Been Selling Antares Pharma, Inc. NASDAQ:ATRS Shares This Year?

2019-05-30 07:00:00 | Antares Pharma to Present at the Jefferies 2019 Healthcare Conference

2019-05-16 17:00:00 | Antares Pharma to Present at the B. Riley FBR Institutional Investor Conference

2019-05-09 14:23:21 | Investors Who Bought Antares Pharma NASDAQ:ATRS Shares Three Years Ago Are Now Up 265%

2019-05-02 21:30:31 | Edited Transcript of ATRS earnings conference call or presentation 2-May-19 12:30pm GMT

2019-05-02 13:49:06 | Antares Pharma Inc ATRS Q1 2019 Earnings Call Transcript

2019-05-02 09:01:47 | Antares Pharma: 1Q Earnings Snapshot

2019-05-02 07:00:00 | Antares Pharma Reports First Quarter 2019 Operating and Financial Results